Basic & Clinical Cancer Research 2017. 9(4):13-21.

The Evaluation of miR-21 Level in Lung Tissue and Plasma of Nsclc Patients
Ayda Arab, Morteza Karimipoor, Shiva Irani, Arda Kiani, Sirous Zeinali, Elham Tafsiri, Kambiz Sheikhy


Background: Lung cancer is one of the most common malignant tumors with poor survival, which is usually diagnosed at advanced stages. In recent years, increasing evidence has revealed that circulating miRNAs exhibit great potential in screening and early detection of various types of cancers including lung cancer. miR-21 is one of the most highly expressed members of the microRNA family in many human cancer types.
Methods: The authors analyzed miR-21 expression in matched tumor and normal tissues and plasma in 17 patients affected with non-small cell lung cancer. Samples were collected from the NSCLC patients before surgery, radiotherapy or chemotherapy. Expression levels of tissue miR-21 were assessed, using TaqMan RT-PCR assay. Expression levels of plasma miR-21 were assessed, using LNA™ RT microRNA PCR primer set and SYBR green qRT-PCR assay.
Results: miR-21 expression was higher in 9 out of 17 patients’ plasma samples. No change in miR-21 expression was observed in 8 plasma samples. In lung tissues, ten patients showed up-regulation of miR-21 and six patients were down-regulated. One patient had no change in miR-21 expression level in tissue samples. The expression level of mir-21 in tissue and plasma was concordant in 6 patients.
Conclusion: It seems that the level of miR-21 in plasma samples of NSCLC patients as a marker for screening needs more investigation.


Non-small cell lung cancer; miR-21; plasma; tissue

Full Text:



Almasi Z, Salehiniya H, Amoori N, Enayatrad M. Epidemiology characteristics and trends of lung cancer incidence in Iran. Asian Pac J Cancer Prev. 2016;17:557-62.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians. 2012;62(4):220-41.

Team NLCSTR, DR A, AM A. Reduced lung-cancer mortality with low-dose computed tomographic screening. NEngl J Med 2011;365:395–409.

Rana, TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36.

S S, EA M, C C. MicroRNA: implication for cancer. Virchows Arch. 2008;452:1-10.

GA C, C S, CD D. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.

C C, RidzonDA, BroomerAJ, Z Z, LeeDH, JT N. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.

A B, D P, F T. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005;204:280-5.

MV I, M F, CG L. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.

K J, EL M, K F. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008;105:7269-74.

DC C, A F-N, AK G. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433-8.

J L, G G, EA M. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.

N Y, N C, E B. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.

WO L, N P, BK P. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67:6031-43.

MV I, R V, G DL. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699-707.

C R, E M, JP H. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677-84.

EJ L, Y G, J J. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046-54.

AE S, TS D, J J. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-52. .

M B, WL F, F P. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-8.

PS M, RK P, EM K, BR F, SK W, EL P-A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.

CH L, S G, HM D. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.

TS W, XB L, BY W. Mature miR-184 as Potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008;14:2588-92.

X C, Y B, L M. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.

EK N, WW C, H J. Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. Gut 2009;58:1375-81.

M T, D I, S K. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-79.

CJ L, SY K, HF T. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010;16:360-4.

AS H, X H, H C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010;3:109-13.

JD A, JR C, EM K, IK R, CC P, DF G, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003- 8.

KC V, BT P, BM S, AT SRaR. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-33.

DO H, G R, U TWaR. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001;47:1488-9.

E C, J RGaM. Shedding microvesicles. Artefacts no more Trends Cell Biol 2009;19:43-1.

N K, H I, Y Y, F T, T MYaO. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-52.

B L, S R, X L, Y W, D G, S Z, et al. MiR-21 overexpression is associated with ac¬quired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 2014;83:146-53.

TR W, S Z, SM A, C A, H A, R B, et al. Anti-miR-21 sup¬presses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol Cancer Res 2015;13:1009-21.

N N, K VR, M V, S S, NM S, F N, et al. Expression, tissue distribution and function of miR-21 in esopha¬geal squamous cell carcinoma. PLoS One 2013;8: e73009.

A E-K, FJ S. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.

Tafsiri E, Darbouy M, Shadmehr MB, Zagryazhskaya A, Alizadeh J, Karimipoor M. Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumor Biology. 2015;36(3):1603-12.

ChenY, ChenJ, WangH, ShiJ, WuK, LiuS. HCV-induced miR-21contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoSPathog. (2013) 9:e1003248.

P G, J C, K C. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706–14.

Arab A, Karimipoor M, Irani S, Kiani A, Zeinali S, Tafsiri E, et al. Potential circulating miRNA signature for early detection of NSCLC. Cancer Genetics 2017;216:150-8.

Koturbash, F, J, Zemp, I, Pogribny aOK. Small moleculeswith big effects: the role of the microRNAome in cancer and carcinogenesis. Mutation Research—Genetic Toxicology and EnvironmentalMutagenesis. 2011;722, no. 2:94–105.

D T, Y S, M W, R Y, Z W, A S, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev 2013;22:540-54.

Yin C, Zhou X, Dang Y, Yan J, Zhang G. Potential role of circulating MiR-21 in the diagnosis and prognosis of digestive system cancer: a systematic review and meta-analysis. Medicine. 2015;94(50).

LuTX, MunitzA, RothenbergME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12 p35 expression. J Immunol (2009) 182:4994–5002.

SonkolyE, WeiT, JansonPC, SaafA, LundebergL, Tengvall-LinderM. MicroRNAs:novel regulators involved in the pathogenesis of psoriasis? . PLoS One (2007) 2:e610.

VoliniaS, CalinGA, LiuCG, AmbsS, CimminoA, PetroccaF. AmicroRNA expression signature of human solid tumors defines cancer gene targets. Proc NatlAcadSciUSA 2006;103:2257–61.

CameronJE, FewellC, YinQ, McBrideJ, WangX, LinZ. Epstein-Barr virus growth/latencyIII program alters cellular microRNA expression. Virology. (2008) 382:257–66.

HuangJ, MaG, FuL, JiaH, ZhuM, LiX. Pseudorabies viral replication is inhibited by anovel target of miR-21. Virology. (2014) 45:(6–457)319–28.

LiuPT, WheelwrightM, TelesR, KomisopoulouE, EdfeldtK, FergusonB. MicroRNA-21 targets the vitamin d-dependent anti microbial pathway in leprosy. NatMed (2012) 18:267–73.

QiuX, DongS, QiaoF, LuS, SongY, LaoY. HBx-mediatedmiR-21upreg- ulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene (2013) 32:3296–305.

WuZ, LuH, ShengJ, LiL. Inductive microRNA-21impairs anti-mycobacterial responses by targeting IL-12 and Bcl-2. FEBS Lett. (2012);586:2459–67.

ShiC, LiangY, YangJ, XiaY, ChenH, HanH. MicroRNA-21knock- out improve the survival rate in DSS induced fatal colitis through pro- tecting against inflammation and tissueinjury. PLoSOne. (2013);8:e66814.

Raitoharju E, Lyytikäinen L-P, Levula M, Oksala N, Mennander A, Tarkka M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219(1):211-7.

E S, G B, P V, M N, M H, H K. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis:miR-21regulates aberrant Tcell responses through regulation of PDCD4 expression. AnnRheumDis. (2011) 70:1496–506.

NH H, AJ S, JA W, M Y, ED B, CC H. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.